Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer

H H Hansen1, M Rørth

  • 1Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

Cancer Chemotherapy and Biological Response Modifiers
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Combination chemotherapy remains the primary treatment for small cell lung cancer, offering high response rates but limited long-term survival. Research is ongoing for non-small cell lung cancer treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of alternative feed additives to medicinal zinc oxide on productivity, diarrhoea incidence and gut development in weaned piglets.

Animal : an international journal of animal bioscience·2020
Same author

Evaluation of the feeding value of Dichrostachys cinerea pods for fattening pigs in Cuba.

Tropical animal health and production·2017
Same author

High plasma triglyceride levels strongly correlate with low kisspeptin in the arcuate nucleus of male rats.

Endocrine regulations·2015
Same author

Technical note: In vitro total gas and methane production measurements from closed or vented rumen batch culture systems.

Journal of dairy science·2014
Same author

Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain.

Developmental neuroscience·2010
Same author

The medullary nail presentation of a new type and report of a case.

Archives of surgery (Chicago, Ill. : 1920)·2010
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Area of Science:

  • Oncology
  • Medical Chemotherapy

Background:

  • Combination chemotherapy with platinum compounds and podophyllotoxins is the standard for small cell lung cancer (SCLC).
  • Current SCLC treatments achieve high response rates (80-90%) but offer limited median survival (11-17 months) and a 5-year survival rate of approximately 5%.

Purpose of the Study:

  • To review current chemotherapy standards and emerging treatments for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
  • To evaluate the role of chemotherapy in different stages of lung cancer and discuss future directions.

Main Methods:

  • Review of current chemotherapy regimens for SCLC, including platinum compounds and podophyllotoxins.
  • Analysis of emerging data on neoadjuvant chemotherapy for Stage IIIa NSCLC.
  • Evaluation of meta-analyses on chemotherapy for advanced NSCLC (Stage IIIb and IV).

Related Experiment Videos

Main Results:

  • SCLC chemotherapy shows high response rates but modest survival benefits, with treatment duration shortened to 5-6 months.
  • Hematopoietic growth factors have not improved SCLC survival but reduce infections during aggressive chemotherapy.
  • Preoperative chemotherapy for Stage IIIa NSCLC shows promise but requires further validation.
  • Chemotherapy for advanced NSCLC offers a small survival benefit (6 weeks) over best supportive care.

Conclusions:

  • Combination chemotherapy is the established backbone for SCLC, with ongoing research for NSCLC.
  • Neoadjuvant chemotherapy for Stage IIIa NSCLC warrants further investigation.
  • Chemotherapy for advanced NSCLC is experimental, necessitating the development of innovative treatments.
  • No significant therapeutic advancements have been reported for mesotheliomas.